A Phase II, Open Label, Two-Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination with Vorinostat For Recurrent or Progressive High-Risk Neuroblastoma Subjects (Optimum Trial)
Details
Age
Child
Locations
Childrens Hospital Colorado
Principal Investigator
Margaret Macy
Study ID
Protocol Number: 16-0742
More information available at ClinicalTrials.gov: NCT03561259
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers